Scottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and post-remission management in severe asthma

Unresolved referenced work

Kept as external metadata until matched

Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype

10.4168/aair.2026.18.1.19 · 2026

An expert consensus framework for asthma remission as a treatment goal

10.1016/j.jaci.2019.12.006 · 2020

Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis

10.1016/s2213-2600(24)00293-5 · 2025

A multidisciplinary team case management approach reduces the burden of frequent asthma admissions

10.1183/23120541.00039-2016 · 2016

Unresolved referenced work

Kept as external metadata until matched

Unresolved referenced work

Kept as external metadata until matched

Unresolved referenced work

Kept as external metadata until matched

Unresolved referenced work

Kept as external metadata until matched

Unresolved referenced work

Kept as external metadata until matched

Delphi methodology in healthcare research: How to decide its appropriateness

10.5662/wjm.v11.i4.116 · 2021

Delphi methodology in health research: how to do it?

10.1016/j.eujim.2015.07.002 · 2015

Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies

10.1016/j.jclinepi.2013.12.002 · 2014

Unresolved referenced work

Kept as external metadata until matched

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

10.1378/chest.125.4.1378 · 2004

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

10.1183/13993003.00413-2021 · 2021

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma

10.1016/j.jaip.2019.08.050 · 2020

Unresolved referenced work

Kept as external metadata until matched

Tiotropium in asthma poorly controlled with standard combination therapy

10.1056/nejmoa1208606 · 2012

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses

10.1007/s41030-023-00234-y · 2023

Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy

2026

Exhaled nitric oxide: a predictor of steroid response

10.1164/rccm.200411-1498oc · 2005

Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis

10.1111/all.70031 · 2026

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

10.1016/s2213-2600(21)00226-5 · 2021

Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma

10.1016/j.jaci.2024.11.024 · 2025

The Role of Biologics in Reducing Mucous Plug Burden in Asthma

10.1111/all.70197 · 2026

Biologics and airway remodeling in asthma: early, late, and potential preventive effects

2024

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

10.1056/nejmoa2401304 · 2024

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

10.1016/s2213-2600(24)00409-0 · 2025

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

10.1056/nejmoa2413181 · 2025

Impact of Smoking on Biological Treatment Response in Patients From the German Severe Asthma (GAN) Registry

10.1016/j.jaip.2025.01.005 · 2025

Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register

10.1016/j.jaip.2023.10.012 · 2024

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP

10.1093/ajrccm/aamag473 · 2026

Asthma remission: what is it and how can it be achieved?

10.1183/13993003.02583-2021 · 2022

FEV(1) Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn

10.1164/rccm.202012-4322le · 2021

Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma

10.1016/j.jaci.2022.10.028 · 2023

Efficacy of biologic therapy on airway hyperresponsiveness in asthma

10.1016/j.anai.2023.02.016 · 2023

New Perspectives on Effects of Biologics on Mannitol Airway Hyperresponsiveness

10.1111/cea.70221 · 2026

Unresolved referenced work

Kept as external metadata until matched

Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study

10.1016/s0140-6736(23)02284-5 · 2024

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

10.1016/s1542-3565(04)00238-1 · doi-reference

How to Adjust Asthma Management Once Asthma Is Controlled on Long-Term Biologic Therapy

10.1016/j.jaip.2025.05.031 · doi-reference

Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study

10.2147/jaa.s567136 · doi-reference

OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial

10.1183/13993003.00404-2024 · doi-reference

The impact of dysfunctional breathing on the assessment of asthma control

10.1016/j.rmed.2016.12.008 · doi-reference

Development and validation of a questionnaire to measure asthma control

10.1034/j.1399-3003.1999.14d29.x · doi-reference